Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
267 employees
NY-based Roivant Sciences is a biopharmaceutical firm dedicated to advancing promising drugs for patient care.
HQ
Founded
2014
Roivant Sciences, founded in New York, is a biopharmaceutical company dedicated to advancing promising drug candidates to improve patient care. The company's core mission is to reinvent the discovery, development, and commercialization of new medicines through its unique model of creating agile, focused subsidiaries known as "Vants." Roivant leverages technology across all stages of drug development and focuses on high-quality execution and rigorous capital allocation to maximize the potential of its drug candidates.
Notable affiliated individuals include founder Vivek Ramaswamy, who has been instrumental in shaping the company's strategic direction. Roivant has attracted significant investment from prominent venture capital firms and has achieved several key milestones, including multiple positive Phase trials and FDA approvals. The company's innovative approach has had a substantial impact on the biopharmaceutical industry, accelerating the development of transformative medicines and improving patient outcomes.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Drug Development
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Roivant Sciences founded?
Roivant Sciences was founded in 2014.
Where is Roivant Sciences's headquarters located?
Roivant Sciences's headquarters is located in New York City, NY, US.
When was Roivant Sciences's last funding round?
Roivant Sciences's most recent funding round was for $230M (USD) in February 2023.
How many employees does Roivant Sciences have?
Roivant Sciences has 267 employees as of Feb 4, 2024.
How much has Roivant Sciences raised to-date?
As of July 05, 2023, Roivant Sciences has raised a total of $2.5B (USD) since Feb 2, 2023.
Add Comparison
Total Raised to Date
$2.5B
USD
Last Update Feb 2, 2023
Last Deal Details
$230M
USD
Feb 2, 2023
Post Ipo Equity
Current Employees
267
Last updated: Feb 4, 2024
No location information available for this company.
Locations
TechCrunch
Lavish parties and moral dilemmas: 4 days with Silicon Valley’s MAGA elite at the RNC
All week at the RNC, I saw an event defined by Silicon Valley. But I also saw the tech elite experience flashes of discordance. © 2024...
Jul 20, 2024
Is this the right Roivant Sciences?
Help us improve our AI - Is this article for the right company?
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts